Abstract
The atypical antipsychotic medication risperidone was evaluated using a double-blind, placebo-controlled design in the treatment of destructive behavior in two individuals with autism. Premedication functional analyses indicated that destructive behavior was maintained by escape from demands, attention, or access to tangible items. For both individuals, destructive behavior during the demand condition was significantly reduced during the medication phases, whereas destructive behavior continued to occur to obtain tangible items (Reggie) and attention (Sean). In addition, there appeared to be a differential effect of the medication on self-injurious behavior (SIB) versus aggression for Sean. Results of the study demonstrate how functional analysis may provide information on those conditions and behaviors that are most likely to be affected by a specific medication.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aman, M. G., & Madrid, A. (1999). Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 253-263.
Fisher, W., Piazza, C., & Page, T. J. (1989). Assessing independent and interactive effects of behavioral pharmacological interventions for a client with dual diagnoses. Journal of Behavior Therapy and Experimental Psychiatry, 20, 241-250.
Fisman, S. F., Steele, M., & Pipher, B. (1998). Risperidone in PDD (letter). Journal of the American Academy of Child and Adolescent Psychiatry, 37, 15-16.
Garcia, D., & Smith, R. G. (1999). Using analog baselines to assess the effects of naltrexone on self-injurious behavior. Research in Developmental Disabilities, 20, 1-21.
Gardner, W. I., Graeber, J. C., & Cole, C. L. (1996). Behavior therapies: A multi-modal diagnostic and intervention model. In J. Jacobson & J. A. Mulick (Eds.), Manual of diagnosis and professional practice in mental retardation (pp. 355-370). Washington, DC: APA Books.
Gillberg, C., & Coleman, M. (1992). The biology of autistic syndromes, 2nd ed. New York: Churchill Livingstone.
Hardan, A., Johnson, K., Johnson, C., & Hrecznyj, B. (1996). Case study: Risperidone treatment of children and adolescents with developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1551-1556.
Horrigan, J. P., & Barnhill, L. J. (1997). Risperidone and explosive aggressive autism. Journal of Autism and Developmental Disorder, 27, 313-322.
Iwata, B. A., Dorsey, M. F., Slifer, K. J., Bauman, K. E., & Richman, G. S. (1994). Toward a functional analysis of self-injury. Journal of Applied Behavior Analysis, 27, 197-209.
Khan, B. (1997). Brief report: Risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults. Journal of Autism and Developmental Disorder, 27, 479-489.
Lindauer, S. L., Zarcone, J. R., Richman, D. M., & Schroeder, S. L. (2002). Acomparison of multiple reinforcer assessments to identify the function of maladaptive behavior. Journal of Applied Behavior Analysis, 35, 209-303.
Luiselli, J. K. (1986). Behavior analysis of pharmacological and contingency management interventions for self-injury. Journal of Behavior Therapy and Experimental Psychiatry, 17, 275-284.
Mace, F. C., & Mauk, J. E. (1995). Bio-behavioral diagnosis and treatment of self-injury. Mental Retardation and Developmental Disabilities Research Reviews, 1, 104-110.
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry, 55, 633-641.
Napolitano, D. A., Jack, S. L., Sheldon, J. B., Williams, D. C., McAdam, D. B., & Schroeder, S. R. (1999). Drug-behavior interactions in persons with mental retardation and developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 322-334.
Nicholson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 372-376.
Northup, J., Fusilier, I., Swanson, V., Huete, J., Bruce, T., Freeland, J., Gulley, V., & Edwards, S. (1999). Further analysis of the separate and interactive effects of methylphenidate and common classroom contingencies. Journal of Applied Behavior Analysis, 32, 35-50.
Northup, J., Fusilier, I., Swanson, V., Roane, H., & Borrero, J. (1997a). An evaluation of methylphenidate as a potential establishing operation for some common classroom reinforcers. Journal of Applied Behavior Analysis, 30, 614-626.
Northup, J., Jones, K., Broussard, C., DiGiovanni, G., Herring, M., Fusilier, I., & Hanchey, A. (1997b). A preliminary analysis of interactive effects between common classroom contingencies and MPH. Journal of Applied Behavior Analysis, 30, 121-125.
Reese, R. M., Hellings, J. A., & Schroeder, S. R. (1999). Treatment methods for destructive and aggressive behaviour in people with severe mental retardation /developmental disabilities. In N. Bouras (Ed.), Psychiatric and behavioural disorders with severe mental retardation/developmental disabilities. London: Cambridge University Press.
Schaal, D. W., & Hackenberg, T. (1994). Toward a functional analysis of drug treatment for behavior problems of people with developmental disabilities. American Journal on Mental Retardation, 99, 123-140.
Schroeder, S. R., Breese, G. R., & Mueller, R. A. (1990). Dopaminergic mechanisms in self-injury. In K. Gadow & M. Wolraich (Eds.), Advances in developmental and behavioral pediatrics (pp. 181-198). London: Jessica Kingsley.
Schroeder, S. R., Oster-Granite, M. L., Berkson, G., Bodfish, J., Breese, G., Cataldo, M., Cook, E., Crnic, L., DeLeon, I., Fisher, W., Harris, J., Horner, R., Iwata, B., Jinnah, H., King, B., Lader, J., Lewis, M., Newell, K., Nyhan, W., Rojahn, J., Sackett, G., Sandman, C., Symons, F., Tessel, R., Thompson, T., & Wong, D. (2001). Self-injurious behavior: Gene-brain-behavior relationships. Mental Retardation and Developmental Disabilities Research Reviews, 7, 3-12.
Sprague, R. L., & Werry, J. S. (1971). Methodology of psychopharmacological studies with the retarded. In N. R. Ellis (Ed.), International Review of Research in Mental Retardation. New York: Academic Press.
Thompson, T., Egli, M., Symons, F., & Delaney, D. (1994). Neurobehavioral mechanisms of drug action in developmental disabilities. In T. Thompson & D. B. Gray (Eds.), Destructive behavior in developmental disabilities: Diagnosis and treatment (pp. 133-188). Thousand Oaks, CA: Sage Publications.
Thompson, T., & Symons, F. J. (1999). Neurobehavioral mechanisms of drug action. In N. A. Wiesler & R. Hanson (Eds.) Challenging behavior of persons with mental health disorders and severe developmental disabilities, (pp. 125-150). Washington, DC: AAMR Monograph Series.
Vanden Borre, R., Vermote, R., Buttiens, M., Thiry, P., Dierick, G., Guetjens, J., Sieben, G., & Heylen, S. (1993). Risperidone as add-on therapy in behavioral disturbances in mental retardation: A double-blind, placebo-controlled cross-over study. Acta Psychiatrica Scandinavica, 87, 167-171.
Zarcone, J. R., Hellings, J. A., Crandall, K., Reese, R. M., Marquis, J., Fleming, K., Shores, R., Williams, D., & Schroeder, S. R. (2001). Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. American Journal on Mental Retardation, 106, 525-538.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Crosland, K.A., Zarcone, J.R., Lindauer, S.E. et al. Use of Functional Analysis Methodology in the Evaluation of Medication Effects. J Autism Dev Disord 33, 271–279 (2003). https://doi.org/10.1023/A:1024402500425
Issue Date:
DOI: https://doi.org/10.1023/A:1024402500425